Table 2:

Response, bone marrow MRD, and combined response/bone marrow MRD by assessment

	Cycle 3 (n=85)	Post-iFCR* (n=85)	Best Response (n=85)
CR†	9 (10·6%)	20 (23·5%)	51 (60·0%)
CRi†	6 (7·1%)	10 (11·8%)	5 (5·9%)
PR	59 (69·4%)	52 (61·2%)	28 (32·9%)
CR or CRi or PR	74 (87·1%)	82 (96·5%)	84 (98·8%)
BM-MRD−	40 (47·1%)	66 (77·6%)	71 (83·5%)
BM-MRD+	38 (44·7%)	14 (16·5%)	14 (16·5%)
BM-MRD UNK	7 (8·2%)	5 (5·9%)	0
CR/MRD−	5 (5·9%)	19 (22·4%)	NA‡
CR/MRD+	4 (4·7%)	1 (1·2%)	NA‡
CRi/MRD−	4 (4·7%)	9 (10·6%)	NA‡
CRi/MRD+	1 (1·2%)	1 (1·2%)	NA‡
PR/MRD−	31 (36·5%)	38 (44·7%)	NA‡
PR/MRD+	28 (32·9%)	12 (14·1%)	NA‡

BM-uMRD=minimal residual disease in the bone marrow. CR=complete response. CRi=complete response with incomplete count recovery. FCR=fludarabine, cyclophosphamide, plus rituximab. MRD=minimum residual disease. NA=not applicable. PR=partial response. UNK=unknown.

^*Post-iFCR evaluations occurred at 1 month instead of 2 months in seven patients due to scheduling issues.

^†CR and CRi were combined when evaluating the primary trial endpoint of BM-uMRD CR post-iFCR.

^‡Because of optional sampling times and missed samples, the best response cannot be defined and are listed as NA.